Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00500045 · ClinicalTrials.gov registry record · Phase 2
Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions
A Phase 2 study, sponsored by Palo Alto Medical Foundation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00500045 is a Phase 2 study that was terminated before completion, run by Palo Alto Medical Foundation. The registered enrollment target is 36 participants.
The verdict
NCT00500045, a Phase 2 study, was terminated before completion, sponsored by Palo Alto Medical Foundation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
The aim of this study is to develop a less risky, yet effective and more sustainable treatment for retinal vein occlusions than the current commonly used approach of repeated intravitreal triamcinolone acetonide (Kenalog) injections. The types of retinal vien occlusion that are being studied include central (CVRO), hemi-retinal (HRVO),and branch (BRVO) retinal vein occlusion. Niacin, (Nicotinic Acid, not Nicotinamide) a B-vitamin, has lipid lowering and vasodilating properties. The combination of Niacin and Prednisolone Acetate steroid eye drops as a non-invasive treatment approach was developed by the Principal Investigator. The Niacin dilates the retinal vessels, hopefully encouraging earlier collateral vessel formation aimed at bypassing the venous obstruction, thus restoring venous outflow. The Prednisolone Acetate steroid eye drops are aimed at reducing vascular leakage and therefore the macular edema in the eye while the Niacin is taking effect.
Interventions
- DRUG nicotinic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2007-02 |
| Est. Completion | 2016-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00500045
The ClinicalTrials.gov registry entry for NCT00500045 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Palo Alto Medical Foundation, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nicotinic acid is the first listed.
NCT00500045 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00500045 about?
NCT00500045 is a clinical study titled "Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions". The aim of this study is to develop a less risky, yet effective and more sustainable treatment for retinal vein occlusions than the current commonly used approach of repeated intravitreal triamcinolone acetonide (Kenalog) injections. The types of retinal vien occlusion that are being studied include...
What is the current status of trial NCT00500045?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2007-02. Estimated completion is 2016-10.
What interventions are being tested in trial NCT00500045?
The interventions under investigation include: nicotinic acid (DRUG).
Who is sponsoring clinical trial NCT00500045?
This trial is sponsored by Palo Alto Medical Foundation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.